SCHEMBL3014192

SCHEMBL3014192

Cc1ccc(Cc2csc(N3CCN(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc1C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
TSHR P16473 2/20 0.47
ALDH1A1 P00352 4/20 0.44
HTT P42858 3/20 0.44
KDM4E B2RXH2 2/20 0.44
LPAR2 Q9HBW0 1/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
GBA1 P04062 2/20 0.43
HSD11B1 P28845 1/20 0.41
CHRM4 P08173 1/20 0.41
PIK3CA P42336 1/20 0.40
MTOR P42345 1/20 0.40
MAPT P10636 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
USP2 O75604 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3015254 0.92 ALDH1A1 (0.42) LMNATSHRALDH1A1HTTKDM4E
SCHEMBL3016050 0.91 ALDH1A1 (0.46) LMNATSHRALDH1A1HTTKDM4E
SCHEMBL3013608 0.90 ALDH1A1 (0.45) LMNATSHRALDH1A1KDM4ELPAR2
SCHEMBL3017242 0.90 ALDH1A1 (0.46) LMNATSHRALDH1A1HTTKDM4E
SCHEMBL3002585 0.90 ALDH1A1 (0.46) LMNATSHRALDH1A1HTTKDM4E
SCHEMBL3018692 0.89 ALDH1A1 (0.48) LMNATSHRALDH1A1HTTKDM4E
SCHEMBL3011321 0.89 MEN1 (0.43) LMNATSHRALDH1A1HTTMEN1
SCHEMBL3014075 0.89 RAB9A (0.46) LMNATSHRALDH1A1HTTMEN1
SCHEMBL3015788 0.89 MEN1 (0.46) LMNATSHRALDH1A1KDM4ELPAR2
SCHEMBL3020518 0.89 THRB (0.45) LMNAALDH1A1HTTKDM4ELPAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885TSHR 3320/4885ALDH1A1 3510/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.